Amphastar Pharmaceuticals, Inc. (AMPH)
NASDAQ: AMPH · Real-Time Price · USD
23.18
0.00 (0.00%)
Sep 4, 2026, 4:00 PM EDT - Market closed
Amphastar Pharmaceuticals Revenue
Amphastar Pharmaceuticals had revenue of $183.90M in the quarter ending June 30, 2026, with 5.44% growth. This brings the company's revenue in the last twelve months to $730.02M, up 1.02% year-over-year. In the year 2025, Amphastar Pharmaceuticals had annual revenue of $719.89M, down -1.65%.
Revenue (ttm)
$730.02M
Revenue Growth
+1.02%
P/S Ratio
1.35
Revenue / Employee
$369,443
Employees
1,976
Market Cap
986.03M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 719.89M | -12.08M | -1.65% |
| Dec 31, 2024 | 731.97M | 87.57M | 13.59% |
| Dec 31, 2023 | 644.40M | 145.41M | 29.14% |
| Dec 31, 2022 | 498.99M | 61.22M | 13.98% |
| Dec 31, 2021 | 437.77M | 87.92M | 25.13% |
| Dec 31, 2020 | 349.85M | 27.49M | 8.53% |
| Dec 31, 2019 | 322.36M | 27.69M | 9.40% |
| Dec 31, 2018 | 294.67M | 54.49M | 22.69% |
| Dec 31, 2017 | 240.18M | -14.99M | -5.87% |
| Dec 31, 2016 | 255.17M | 3.65M | 1.45% |
| Dec 31, 2015 | 251.52M | 41.06M | 19.51% |
| Dec 31, 2014 | 210.46M | -19.22M | -8.37% |
| Dec 31, 2013 | 229.68M | 25.36M | 12.41% |
| Dec 31, 2012 | 204.32M | 85.97M | 72.63% |
| Dec 31, 2011 | 118.36M | -12.38M | -9.47% |
| Dec 31, 2010 | 130.74M | 46.46M | 55.13% |
| Dec 31, 2005 | 84.28M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Phibro Animal Health | 1.52B |
| ANI Pharmaceuticals | 978.38M |
| Evotec SE | 819.47M |
| Collegium Pharmaceutical | 808.21M |
| Pacira BioSciences | 746.16M |
| Ironwood Pharmaceuticals | 389.32M |
| Xeris Biopharma Holdings | 335.41M |
| Harrow | 275.59M |
AMPH News
- 7 days ago - Amphastar Pharmaceuticals to Present at the Wells Fargo 21st Annual Healthcare Conference - PRNewsWire
- 20 days ago - Amphastar price target raised to $23 from $20 at Barclays - TheFly
- 4 weeks ago - Amphastar price target raised to $20 from $19 at Wells Fargo - TheFly
- 4 weeks ago - Amphastar Pharmaceuticals Earnings Call Transcript: Q2 2026 - Transcripts
- 4 weeks ago - Amphastar Pharmaceuticals Earnings release: Q2 2026 - Filings
- 4 weeks ago - Amphastar Pharmaceuticals Slides: Q2 2026 - Filings
- 4 weeks ago - Amphastar Pharmaceuticals Quarterly report: Q2 2026 - Filings
- 4 weeks ago - Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2026 - PRNewsWire